GlaxoSmithKline Newsroom

Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children

Benzinga04:57

United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis

Benzinga00:06

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

BenzingaDec 13 02:13

Barclays Remains a Hold on GlaxoSmithKline (GSK)

TipRanksDec 12 15:35 · Ratings

Anaptys Scraps Development of ANB032, Stock Plunges 33%

Seeking AlphaDec 12 00:52

TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $45

Futu NewsDec 11 23:32 · Ratings

GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?

Zacks Dec 11 22:30

Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

TipRanksDec 11 20:35 · Ratings

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex

BenzingaDec 11 02:14

India Drug Delivery Devices Market 2024, With Profiles of Pfizer, Novartis, GlaxoSmithKline, India Medtronic, Cardinal Health, B. Braun Medical, Sun Pharmaceutical, 3M, Cipla & Bayer Zydus Pharma

Yahoo FinanceDec 10 20:25

GSK, Relation Therapeutics Partner to Advance Osteoarthritis, Fibrotic Disease Treatments

WSJDec 10 16:24

Glaxosmithkline (GSK.US) drugs reduce the risk of death by 42% in multiple myeloma studies.

Glaxosmithkline (GSK.US) reported that a study shows its drug belantamab mafodotin can reduce the risk of death for patients with multiple myeloma at first relapse or post-relapse by 42%.

Zhitong FinanceDec 10 14:20

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT NewswiresDec 10 04:56

Sector Update: Health Care

MT NewswiresDec 10 04:32

GSK's DREAMM-7 Trial Shows Sustained Overall Survival Benefit For Belantamab Mafodotin Combination Versus Daratumumab Combination; Benefit Seen Early And Maintained Through Follow-up, Reducing The Risk Of Death By 42% In Multiple Myeloma At Or After...

BenzingaDec 10 02:42

GSK: Blenrep Is Treatment for Relapsed/Refractory Multiple Myeloma

Dow JonesDec 10 02:30

GSK: Data Is For Patients With Multiple Myeloma at or After First Relapse

Dow JonesDec 10 02:30

GSK: Data Supports Potential for Blenrep Combinations to Become Standard of Care

Dow JonesDec 10 02:30

GSK: Data Projects Patients on Blenrep Combination To Survive Nearly Three Years Longer Compared to Standard of Care

Dow JonesDec 10 02:30

GSK: Blenrep Combination Late-Stage Trial Reduced Risk of Death by 42% in Patients With Multiple Myeloma at or After First Relapse

Dow JonesDec 10 02:30